Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444203 · ClinicalTrials.gov registry record
Transformative Research in Diabetic Nephropathy 2.0
A clinical trial of Diabetes Mellitus, Type 2 and Kidney Diseases, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07444203: Recruiting study of Diabetes Mellitus, Type 2 and Kidney Diseases, sponsored by University of Pennsylvania.
NCT07444203 is a study of Diabetes Mellitus, Type 2 and Kidney Diseases that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 200 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07444203, a study of Diabetes Mellitus, Type 2 and Kidney Diseases, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care. The main questions this study aims to answer are: * Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them? * Are these kidney tissue patterns linked with how kidney health changes over time? Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines. Participants will: Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
Primary Outcome
Change/differences in kidney tissue molecular "fingerprint" (molecular pathways / spatial gene expression signatures derived from archived kidney tissue) comparing participants exposed to sodium-glucose cotransporter 2 inhibitors versus controls and participants on other therapies. Tissue profiling includes single-cell spatial transcriptomics with differential expression and pathway analyses stratified by therapy exposure.
Conditions Studied
Interventions
- DRUG Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
- DRUG Renin-angiotensin-aldosterone system blockade
- DRUG Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- DRUG Mineralocorticoid Receptor Antagonists(MRAs)
Study Locations (1)
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-11-12 |
What NCT07444203 shows while recruiting
NCT07444203 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first listed.
NCT07444203 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07444203 about?
NCT07444203 is a clinical study titled "Transformative Research in Diabetic Nephropathy 2.0". The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect...
What is the current status of trial NCT07444203?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-11-12. Estimated completion is 2028-11-12.
What conditions does trial NCT07444203 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Kidney Diseases, Renal Insufficiency, Chronic, Diabetic Nephropathies.
What interventions are being tested in trial NCT07444203?
The interventions under investigation include: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (DRUG), Renin-angiotensin-aldosterone system blockade (DRUG), Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (DRUG), Mineralocorticoid Receptor Antagonists(MRAs) (DRUG).
Who is sponsoring clinical trial NCT07444203?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07444203 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07444203's enrollment target sits among peer trials
200 150th of 348 higher than 196 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI